Jaguar health and filament health, with funding from one small planet, form joint venture magdalena biosciences to develop botanical pharmaceutical drug candidates for mental health illnesses

New venture aligns with jaguar's mental health entheogen therapeutics initiative (eti) and filament's corporate mission to develop novel, natural prescription medicines from plants magdalena biosciences will leverage jaguar's proprietary medicinal plant library and filament's proprietary drug development technology magdalena biosciences is currently valued at us$5.0 million based on initial and tranched funding of us$1.0 million from one small planet san francisco, ca / accesswire / january 10, 2023 / jaguar health, inc. (nasdaq:jagx), filament health corp. (neo:fh), (otcqb:flhlf) and one small planet, llc today announced the formation of a u.s.-based joint venture named magdalena biosciences, inc. to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (adhd) in adults. initial funding of us$1,000,000 will be invested by boulder, colorado-based one small planet, founded by will peterffy.
JAGX Ratings Summary
JAGX Quant Ranking